# Approach to the Floppy Infant

## Overview

Neonatal hypotonia is a common clinical presentation with a broad differential diagnosis. The key distinction is between central causes (brain or spinal cord) and peripheral causes (anterior horn cell, nerve, neuromuscular junction, or muscle). Central causes are more common, accounting for approximately 60-80% of cases. A systematic approach combining history, examination, and targeted investigations is essential. Advances in genetic testing and gene therapy, especially for spinal muscular atrophy (SMA), have made early diagnosis critical for treatment.

## Clinical Assessment

### History

The pregnancy history may reveal reduced fetal movements, polyhydramnios (from swallowing difficulty), or breech presentation. Delivery history may include birth asphyxia or complicated delivery. Family history should assess for consanguinity, neuromuscular disease, and early infant deaths. The neonatal course may be notable for feeding difficulties, respiratory insufficiency, or seizures. The developmental trajectory should be characterized as static versus progressive, with progressive worsening suggesting degenerative disease.

### Examination of the Hypotonic Infant

Observation assesses posture (frog-leg position), spontaneous movements, respiratory pattern, and facial expression. The traction response (pull-to-sit) evaluates head lag, which normally diminishes by 4-5 months. On ventral suspension, a hypotonic infant drapes over the hand like an inverted U, whereas a normal infant maintains some antigravity posture. On vertical suspension, the hypotonic infant "slips through" the examiner's hands, while a normal infant can be held under the axillae.

Deep tendon reflexes are key to localization: in central hypotonia, reflexes are present or brisk, whereas in peripheral hypotonia, reflexes are diminished or absent. Muscle bulk and fasciculations should be assessed; wasting and fasciculations (especially of the tongue) suggest anterior horn cell disease such as SMA. Alertness and interaction are typically preserved in peripheral causes but often impaired in central causes.

### Distinguishing Central vs. Peripheral Hypotonia

| Feature | Central Hypotonia | Peripheral Hypotonia |
|---------|------------------|---------------------|
| Deep tendon reflexes | Normal or increased | Decreased or absent |
| Muscle bulk | Preserved | Wasted |
| Fasciculations | Absent | May be present (SMA) |
| Seizures | Common | Rare |
| Cognition | Often impaired | Usually preserved |
| Dysmorphic features | Common | Less common |
| Hand fisting | Present | Absent |
| Key examples | HIE, Down syndrome, Prader-Willi | SMA, congenital myopathy, botulism |

Central hypotonia is characterized by normal or increased deep tendon reflexes, preserved muscle bulk, absence of fasciculations, common seizures, often-present cognitive impairment, common dysmorphic features, and hand fisting. Peripheral hypotonia features decreased or absent deep tendon reflexes, wasted muscles, possible fasciculations (especially in SMA), rare seizures, usually preserved cognition, and fewer dysmorphic features. Antigravity movements are reduced or absent in both.

<image>Clinical examination of the floppy infant demonstrating key maneuvers: pull-to-sit showing significant head lag, ventral suspension with infant draped over hand in inverted U position, vertical suspension with infant slipping through hands, and frog-leg posture at rest, with annotations distinguishing central versus peripheral hypotonia patterns</image>

## Central Causes of Hypotonia

### Hypoxic-Ischemic Encephalopathy (HIE)

HIE is the most common perinatal cause of central hypotonia. The history includes birth asphyxia, low Apgar scores, and neonatal seizures. Brain MRI shows characteristic patterns (watershed, basal ganglia/thalamus). Therapeutic hypothermia within 6 hours of birth is the treatment for moderate-to-severe HIE.

### Chromosomal/Genetic Syndromes

Down syndrome (Trisomy 21) is the most common genetic cause of hypotonia, presenting with characteristic dysmorphic features and cardiac defects. Prader-Willi syndrome causes severe neonatal hypotonia with poor feeding and hypogonadism, followed later by hyperphagia and obesity; diagnosis is by DNA methylation analysis (detecting more than 99% of cases), which identifies absent paternal contribution at 15q11-13. Angelman syndrome presents with hypotonia, seizures, severe intellectual disability, and a happy demeanor. Congenital myotonic dystrophy type 1 is maternally transmitted and presents with severe neonatal hypotonia, respiratory failure, facial diplegia, and clubfoot; the mother may have subtle myotonia (grip, percussion), and diagnosis involves identifying the CTG trinucleotide repeat expansion in the DMPK gene.

### Brain Malformations

Lissencephaly, polymicrogyria, schizencephaly, and holoprosencephaly are often associated with seizures, microcephaly, and developmental delay. Brain MRI is diagnostic.

### Metabolic Disorders

Peroxisomal disorders (Zellweger spectrum) present with craniofacial dysmorphism, hepatomegaly, seizures, and elevated very long-chain fatty acids. Mitochondrial disorders involve multisystem involvement, lactic acidosis, and MRI white matter changes. Organic acidemias and aminoacidopathies are additional considerations. Pompe disease (acid maltase deficiency) can present as both central and peripheral hypotonia with cardiomegaly.

## Peripheral Causes of Hypotonia

### Spinal Muscular Atrophy (SMA)

SMA is an autosomal recessive condition caused by homozygous deletion or mutation of the SMN1 gene on chromosome 5q. SMN2 copy number modifies severity (more copies yield milder disease). Before disease-modifying therapy, it was the most common genetic cause of infant death.

SMA Type 1 (Werdnig-Hoffmann) has onset before 6 months with severe weakness; affected infants never achieve sitting. Tongue fasciculations and paradoxical breathing (bell-shaped chest) are characteristic, and without treatment, death from respiratory failure occurs by age 2. SMA Type 2 has onset between 6 and 18 months; the child achieves sitting but never walks independently. SMA Type 3 (Kugelberg-Welander) has onset after 18 months; affected children are ambulatory with slowly progressive weakness.

#### Disease-Modifying Therapies

| Therapy | Mechanism | Route | Dosing Schedule | FDA Approval | Key Trial |
|---------|-----------|-------|----------------|-------------|-----------|
| Nusinersen (Spinraza) | ASO; increases SMN2 protein | Intrathecal | Loading then every 4 months (lifelong) | All ages | ENDEAR |
| Onasemnogene (Zolgensma) | AAV9 gene replacement; provides SMN1 | Single IV dose | Once | <2 years | STR1VE |
| Risdiplam (Evrysdi) | Oral SMN2 splicing modifier | Oral daily | Daily (lifelong) | All ages (≥2 months) | FIREFISH |

Nusinersen (Spinraza) is an antisense oligonucleotide given by intrathecal injection that increases SMN2 protein production. It requires loading doses followed by dosing every 4 months and is lifelong treatment. The ENDEAR trial demonstrated significant improvement in motor function in SMA type 1. Onasemnogene abeparvovec (Zolgensma) is an AAV9-based gene replacement therapy delivered as a single IV dose that provides a functional SMN1 gene. It is FDA-approved for children under 2 years and costs approximately $2.1 million per dose. It is most effective when given presymptomatically through newborn screening identification. Risdiplam (Evrysdi) is an oral SMN2 splicing modifier given daily and is approved for all ages. Early treatment is critical, with outcomes dramatically better when therapy is initiated before symptom onset.

### Congenital Myopathies

Nemaline myopathy features rod-shaped structures on muscle biopsy with facial weakness and respiratory insufficiency. Central core disease is associated with malignant hyperthermia susceptibility (RYR1 mutations). Myotubular myopathy is X-linked, with a severe neonatal form causing respiratory failure. Genetic testing is increasingly replacing muscle biopsy for diagnosis.

### Congenital Muscular Dystrophies

Merosin-deficient CMD presents with white matter changes on MRI, elevated CK, and laminin alpha-2 deficiency. Dystroglycanopathies (Fukuyama CMD, Walker-Warburg syndrome, Muscle-Eye-Brain disease) feature brain malformations combined with muscle disease. Ullrich CMD involves collagen VI mutations causing hyperlaxity with contractures.

### Congenital Myasthenic Syndromes

These are genetic disorders of the neuromuscular junction (not autoimmune) that present with fluctuating weakness, fatigability, ptosis, and ophthalmoplegia. Response to pyridostigmine is variable, with some subtypes worsening. Genetic testing for DOK7, RAPSN, and CHRNE mutations confirms the diagnosis.

### Transient Neonatal Myasthenia Gravis

This occurs in infants of mothers with autoimmune myasthenia gravis through passive transfer of anti-AChR antibodies across the placenta. It presents at birth or within the first 48 hours with weak cry, poor feeding, and generalized hypotonia. It self-resolves in 2-4 weeks as maternal antibodies clear. Supportive care is the mainstay, with pyridostigmine given if severe.

### Infantile Botulism

Infantile botulism results from ingestion of Clostridium botulinum spores (from honey or soil), with toxin produced in the infant gut. It typically affects infants aged 2 weeks to 6 months. The presentation is a descending paralysis: constipation (often the first sign), weak cry, poor feeding, hypotonia, loss of head control, and dilated sluggish pupils. Diagnosis is by stool toxin assay and stool culture for C. botulinum. Treatment is BabyBIG (human botulism immune globulin), which reduces hospitalization and mechanical ventilation duration. Prevention is straightforward: no honey before age 1 year.

<image>Diagnostic algorithm for neonatal hypotonia showing initial clinical differentiation of central versus peripheral causes based on reflexes, muscle bulk, cognition, and seizures, with subsequent workup branches: central (MRI brain, genetic testing for chromosomal disorders, metabolic screen) and peripheral (SMN1 gene testing, CK level, EMG/NCS, muscle biopsy, and targeted genetic panels)</image>

## Diagnostic Workup

### Initial Investigations

CK (creatine kinase) is elevated in muscular dystrophies and some myopathies but normal in SMA, central causes, and NMJ disorders. Genetic testing should include SMN1 deletion analysis (obtained early if SMA is suspected), chromosomal microarray, methylation studies (for Prader-Willi), CTG repeat analysis (for congenital myotonic dystrophy, especially if the mother is affected), and whole exome or genome sequencing (increasingly used as first-line for undiagnosed hypotonia). MRI brain is indicated for all cases of suspected central hypotonia. Metabolic studies include ammonia, lactate, acylcarnitine profile, urine organic acids, and very long-chain fatty acids.

### When Needed

EMG and nerve conduction studies help localize to anterior horn cell, nerve, NMJ, or muscle, though they are technically challenging in neonates. Repetitive nerve stimulation showing a decremental response indicates NMJ disorders. Muscle biopsy is increasingly being replaced by genetic testing but remains useful for some congenital myopathies and dystrophies. Nerve biopsy is rarely needed and is reserved for suspected congenital neuropathies.

## Newborn Screening for SMA

The screening uses a TREC-based or SMN1-specific assay on the newborn dried blood spot and is now included in the Recommended Uniform Screening Panel (RUSP) in the US and many countries. It enables presymptomatic identification and early treatment. Presymptomatic treatment with gene therapy or nusinersen results in near-normal motor development. From a cost-effectiveness standpoint, treatment before symptom onset prevents the need for ventilator dependence and intensive supportive care.

<image>Timeline showing the impact of newborn screening and early treatment for SMA, comparing outcomes with presymptomatic treatment (near-normal motor milestones with gene therapy or nusinersen), early symptomatic treatment (improved but suboptimal outcomes), and late or no treatment (progressive weakness, respiratory failure, death in SMA type 1), emphasizing the critical therapeutic window</image>

## Clinical Pearls

The most important clinical distinction is central versus peripheral hypotonia, and deep tendon reflexes are the key differentiator. Tongue fasciculations in a floppy infant are virtually pathognomonic for SMA, and SMN1 gene testing should be ordered immediately. Prader-Willi syndrome should be considered in any neonate with severe hypotonia and poor feeding, especially if male with cryptorchidism. Congenital myotonic dystrophy is maternally inherited, so the mother should be examined for grip myotonia or frontal balding if this diagnosis is suspected. Honey should never be given to infants under 1 year because infant botulism is preventable. If the clinical picture is progressive (getting worse over time), the diagnosis should be reconsidered, as CP and most congenital myopathies are static; progressive worsening suggests metabolic or degenerative disease. SMA newborn screening has made early identification possible, and presymptomatic treatment dramatically changes outcomes.

## Key Controversy: SMA Newborn Screening and Gene Therapy Cost-Effectiveness

SMA newborn screening is now on the RUSP, but implementation varies by state and country. Gene therapy (Zolgensma) at approximately $2.1 million per dose is one of the most expensive therapies ever developed, and cost-effectiveness is debated. Arguments in favor include prevention of devastating disability, reduced lifetime healthcare costs (ventilation, feeding support, hospitalizations), and dramatic improvement in quality of life. Arguments against include uncertain very long-term efficacy and durability (gene therapy is relatively new), cost burden on healthcare systems, and equity concerns about global access. Nusinersen and risdiplam are alternatives but require lifelong administration, with ongoing costs that may exceed single-dose gene therapy over a lifetime. Ethical considerations include treatment of presymptomatic infants with high SMN2 copy numbers who may have milder disease and uncertain natural history. International disparities persist, with newborn screening and treatment access largely limited to high-income countries.

## References
- Darras BT. Spinal Muscular Atrophies. Pediatr Clin North Am. 2015;62(3):743-766.
- Mendell JR, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy (Zolgensma). N Engl J Med. 2017;377(18):1713-1722.
- Finkel RS, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy (ENDEAR). N Engl J Med. 2017;377(18):1723-1732.
- Cassidy SB, et al. Prader-Willi Syndrome. Genet Med. 2012;14(1):10-26.
- Prasad AN, Bhargava R. Assessment and Management of the Floppy Infant. Paediatr Child Health. 2015;25(11):498-505.
- Pechmann A, et al. Spinal Muscular Atrophy: New Therapies, New Challenges. J Child Neurol. 2023;38(3-4):169-178.